Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication

Aya, Francisco; González Navarro, E. Azucena; Martínez, Clara M.; Carcelero, Esther; Arance, Ana

doi:http://dx.doi.org/10.2217/imt-2020-0274

Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication

Citation

Aya F, González-Navarro EA, Martínez C, Carcelero E, Arance A. Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. Immunotherapy. 2021;13(9):745-52. DOI: 10.2217/imt-2020-0274

Abstract

Aim: To evaluate the safety of rechallenge with a different anti-PD-1 antibody after an immune-related adverse event (irAE) that has prompted the discontinuation of anti-PD-1 therapy. Patients & methods: We describe two patients with metastatic melanoma who developed potentially disabling and early irAEs following anti-PD-1 treatment. Therapy was discontinued and toxicities resolved with corticosteroids. Results: Rechallenge switching to an alternative anti-PD-1 antibody did not lead to a new or recurrent irAE. Conclusion: Switching to a different anti-PD-1 antibody when resuming therapy after an irAE might be a safe strategy and warrants further investigation. Structural and biological differences between antibodies might explain the different safety outcomes.